Pathogenic mechanisms and experimental models of multiple sclerosis (Q37728003)

22 August 2017

1 reference

title

Pathogenic mechanisms and experimental models of multiple sclerosis (English)

1 reference

22 August 2017

0 references

Anthony Slavin

1

1 reference

22 August 2017

Louise Kelly-Modis

2

1 reference

22 August 2017

Mark Labadia

3

1 reference

22 August 2017

Kelli Ryan

4

1 reference

22 August 2017

Maryanne L Brown

5

1 reference

22 August 2017

1 November 2010

1 reference

22 August 2017

1 reference

22 August 2017

43

1 reference

22 August 2017

7

1 reference

22 August 2017

504-513

1 reference

Genes, environment, and susceptibility to multiple sclerosis

22 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

From genes to function: the next challenge to understanding multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Multiple sclerosis--the plaque and its pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Interferon-beta1a for the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Identification and development of new therapeutics for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Risk alleles for multiple sclerosis identified by a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

The expanding genetic overlap between multiple sclerosis and type I diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

CD226 Gly307Ser association with multiple autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Osteopontin polymorphisms and disease course in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Three or more routes for leukocyte migration into the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

The contribution of gammadelta T cells to the pathogenesis of EAE and MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

B cells and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Experimental autoimmune encephalomyelitis repressed by microglial paralysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Cutting edge: central nervous system plasmacytoid dendritic cells regulate the severity of relapsing experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Human astrocytes are only partially competent antigen presenting cells. Possible implications for lesion development in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

EAE: an immunologist's magic eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Acute and relapsing experimental autoimmune encephalomyelitis in IL-4- and alpha/beta T cell-deficient C57BL/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Peripheral blood CD4+ T lymphocytes from multiple sclerosis patients are characterized by higher PSGL-1 expression and transmigration capacity across a human blood-brain barrier-derived endothelial cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

A molecular trio in relapse and remission in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Elevated osteopontin levels in active relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

The presence of immunoreactive myelin basic protein peptide in urine of persons with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674733

10.3109/08916931003674733

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference